The Children's Vaccine Initiative: Continuing Activities

Questions? Call 800-624-6242

About | Ordering | New

LoginRegister

| Items in cart [0]

Rights & Permissions

Free Resources

Display this book
on your site!

Related Titles

The Children's Vaccine Initiative: Continuing Activities (1995)
Institute of Medicine (IOM)

Citation Manager Export the bibliographic data for this book in your chosen format
Web Search Builder Use this book's key terms to search within this book, across our collection, or across the Web.
Skim This Chapter Skim this chapter and use this chapter's key terms to search within this book.
Reference Finder Paste in your own text to find books that relate to your topic.

Citation Manager

. "OVERCOMING SCIENTIFIC AND TECHNOLOGICAL BARRIERS." The Children's Vaccine Initiative: Continuing Activities. Washington, DC: The National Academies Press, 1995.

Please select a format:

Page
9


E-mail Share on facebook Facebook Share on delicious Delicious Share on stumbleupon Stumble Share on twitter Twitter More Sharing ServicesMore

The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy.

The Children’s Vaccine Initiative: Continuing Activities: A Summary of Two Workshops Held September 12–13 and October 25–26, 1994

TABLE 1 Characteristics of Conjugate Pneumococcal Vaccines

Organization	Protein Carrier	Linker Technology	Saccharide Length	Vaccine Serotypes in Clinical Trials	Phase of Trials
Pasteur-Merieux Connaught	Tetanus toxoid Diphtheria toxoid	Short linker (new technology)	—	6, 14, 19, 23 (propose to add 3, 4, 9, and 18)	Phase I/II
Lederle-Praxis	CRM 197	Short linker	Short	6, 14, 18, 19, 23 (propose to add 4 and 9 for United States and 1 and 5 for “developing country” formulations)	Phase I/II
Merck	OMP-meningococcus B	Bivalent linker	Long	4, 6, 9, 14, 18, 19, 23	Phase I/II
University of Rochester	CRM 197, tetanus toxoid	Reductive amination	Short	6, 14, 19, 23 (amine)	Phase I
National Institute of Child Health and Human Development	Tetanus toxoid	Short linker (6-carbon)	Long	6, 12	Phase I
Dutch-Nordic Consortium	Tetanus toxoid	Thioether	Variable	None (propose to use a 4-valent vaccine similar to Merck’s)	None
SOURCE: National Institute of Allergy and Infectious Diseases, 1994.